Beaumont Heart and Vascular Center of Excellence
 

Toray Satake hot balloon ablation system uses heat to treat heart rhythm disorder

Beaumont is the first center outside of Japan to use a new balloon ablation technology to treat atrial fibrillation, the most common heart rhythm disorder that affects about 3 million people in the U.S.

Named after its Japanese inventor, Dr. Shutaro Satake, the treatment uses a special catheter equipped with a balloon that is inflated with liquid then heated to burn or ablate the source of atrial fibrillation in the heart.

“This treatment is designed for people with paroxysmal atrial fibrillation – a rapid, irregular heart rhythm that comes and goes on its own and has not responded to anti-arrythmic drugs,” says Dr. Haines.

Learn More

 

 

In October 2013, the FDA approved the use of the MitraClip to treat patients with degenerative mitral valve regurgitation. Beaumont is the first hospital in Michigan to implant the commercially approved MitraClip to help high-risk patients with degenerative mitral valve regurgitation. Surgery is typically not an option these patients because of the severity of their condition.

“The MitraClip gives us the opportunity to help patients with severe mitral valve regurgitation that in the past did not have any options,” stated George Hanzel, M.D., Director of Cardiac Catheterization Laboratories at Beaumont, Royal Oak.

Learn More

 

1 | 2

For Patients
State of the Heart

For Physicians
Heart & Vascular Update

Beaumont offers a series of
7 tests for $70 to determine
your risk for heart disease.
Are you at risk?


Identify Heart Disease Risks
Heart and Vascular Clinic Specialty Spotlight

Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement (TAVR) is a new option for the treatment of aortic stenosis, a common heart problem affecting approximately 1 million patients in the U.S. each year. Although surgical aortic valve replacement is the gold standard for the treatment of severe aortic stenosis, 60 percent of patients are too high-risk to undergo traditional surgery.

TAVR, an innovative minimally invasive option for these high-risk patients, was approved by the Food and Drug Administration in November 2011. In 2005, Beaumont was the first hospital in North America to perform this procedure and currently is one of only a few centers in Michigan to offer TAVR. 

To connect to a heart and vascular specialist or to schedule an appointment, call 800-633-7377.